...
首页> 外文期刊>Nature cell biology >A cell-intrinsic role for TLR2-MYD88 in intestinal and breast epithelia and oncogenesis.
【24h】

A cell-intrinsic role for TLR2-MYD88 in intestinal and breast epithelia and oncogenesis.

机译:TLR2-MYD88在肠和乳腺上皮细胞和肿瘤发生中的细胞内在作用。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

It has been postulated that there is a link between inflammation and cancer. Here we describe a role for cell-intrinsic toll-like receptor-2 (TLR2; which is involved in inflammatory response) signalling in normal intestinal and mammary epithelial cells and oncogenesis. The downstream effectors of TLR2 are expressed by normal intestinal and mammary epithelia, including the stem/progenitor cells. Deletion of MYD88 or TLR2 in the intestinal epithelium markedly reduces DSS-induced colitis regeneration and spontaneous tumour development in mice. Limiting dilution transplantations of breast epithelial cells devoid of TLR2 or MYD88 revealed a significant decrease in mammary repopulating unit frequency compared with the control. Inhibition of TLR2, its co-receptor CD14, or its downstream targets MYD88 and IRAK1 inhibits growth of human breast cancers in vitro and in vivo. These results suggest that inhibitors of the TLR2 pathway merit investigation as possible therapeutic and chemoprevention agents.
机译:据推测,炎症和癌症之间存在联系。在这里,我们描述了正常肠道和乳腺上皮细胞中的细胞内Toll样受体2(TLR2;参与炎症反应)信号传导的作用。 TLR2的下游效应子由正常的肠道和乳腺上皮表达,包括干/祖细胞。肠道上皮中MYD88或TLR2的缺失显着降低了DSS诱导的小鼠结肠炎的再生和自发性肿瘤的发展。缺乏TLR2或MYD88的乳腺上皮细胞的有限稀释移植显示,与对照相比,乳腺繁殖单位频率显着降低。抑制TLR2,其共受体CD14或下游靶点MYD88和IRAK1可以在体外和体内抑制人乳腺癌的生长。这些结果表明,TLR2途径的抑制剂值得研究作为可能的治疗剂和化学预防剂。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号